高剂量依托泊苷（VP16 - 213）治疗肝细胞癌的2期研究。
Phase 2 study of high dose etoposide (VP16-213) in hepatocellular carcinoma.
作者信息
Shiu W, Mok S D, Leung N, Li M, Zacharia A, Li A, Martin C
出版信息
Jpn J Clin Oncol. 1987 Jun;17(2):113-5.
PMID:3039199
Abstract
A phase II study of etoposide (VP16-213) in hepatocellular carcinoma was conducted among 18 Chinese patients. There was no observable tumour response but the treatment was relatively well tolerated with an overall median survival interval of 74 days.
摘要
对18名中国患者进行了依托泊苷（VP16 - 213）治疗肝细胞癌的II期研究。未观察到肿瘤反应，但该治疗耐受性相对良好，总体中位生存间隔为74天。
Zotero 插件